Does Rallies show 13F holders for BOLT?

Yes. Rallies tracks hedge fund and 13F ownership data for BOLT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BOLT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BOLT. It does not provide personalized investment advice.

BOLT (Bolt Biotherapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Bolt Biotherapeutics, Inc. Common Stock (BOLT) is a publicly traded Healthcare sector company. As of May 21, 2026, BOLT trades at $4.63 with a market cap of $8.38M and a P/E ratio of -0.28. BOLT moved -6.25% today. Year to date, BOLT is -18.55%; over the trailing twelve months it is -30.09%. Its 52-week range spans $3.91 to $14.36. Analyst consensus is buy with an average price target of $30.33. Rallies surfaces BOLT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BOLT stock?

Hedge funds tracked by Rallies that own BOLT include Orbimed Advisors. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bolt Biotherapeutics, Inc. Common Stock.

BOLT Key Metrics

Key financial metrics for BOLT
Metric	Value
Price	$4.63
Market Cap	$8.38M
P/E Ratio	-0.28
EPS	$-16.40
Dividend Yield	0.00%
52-Week High	$14.36
52-Week Low	$3.91
Volume	0
Avg Volume	0
Revenue (TTM)	$6.50M
Net Income	$-29.58M
Gross Margin	0.00%

Top Hedge Funds Holding BOLT

Orbimed Advisors holds 1.54M shares of BOLT, changed +0.00% as of Mar 31, 2024.

Latest BOLT News

Bolt Biotherapeutics Reports $4.31 Q1 Loss, Misses Revenue Estimates — May 12, 2026

Recent BOLT Insider Trades

Quinn William P. bought 125 (~$575.875) on Dec 5, 2025.
Nemec Sarah bought 125 (~$575.875) on Dec 5, 2025.
Nemec Sarah bought 125 (~$686.5) on Jun 6, 2025.

BOLT Analyst Consensus

3 analysts cover BOLT: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.33.

Common questions about BOLT

Who owns BOLT stock?: Hedge funds tracked by Rallies that own BOLT include Orbimed Advisors. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bolt Biotherapeutics, Inc. Common Stock.
Does Rallies show 13F holders for BOLT?: Yes. Rallies tracks hedge fund and 13F ownership data for BOLT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BOLT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BOLT. It does not provide personalized investment advice.